Yahoo
OTC Markets OTCQB - Delayed Quote USD

Vivos Inc. (RDGL)

0.0501 -0.0012 (-2.24%)
As of 12:03:52 PM EDT. Market Open.
Chart Range Bar
Loading chart for RDGL
  • Previous Close 0.0512
  • Open 0.0542
  • Bid 0.0483 x 7000000
  • Ask 0.0545 x 8500000
  • Day's Range 0.0501 - 0.0560
  • 52 Week Range 0.0471 - 0.1244
  • Volume 238,916
  • Avg. Volume 1,501,807
  • Market Cap (intraday) 24.76M
  • Beta (5Y Monthly) -0.70
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Vivos Inc., a radiation oncology medical device company, engages in the development of yttrium-90-based precision radionuclide therapy devices for the treatment of non-resectable tumors in the United States. The company develops RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing PLGA-g-PEG polymers; PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents; Duncan Chiller, a general laboratory equipment for non-water localized chilling; and other products under the Alpha-Gel, Beta-Gel, Gamma-Gel, and Peltier Chiller brands. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Kennewick, Washington.

radiogel.com

1

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RDGL
27.29%
S&P 500 (^GSPC)
13.13%

1-Year Return

RDGL
53.40%
S&P 500 (^GSPC)
20.09%

3-Year Return

RDGL
19.45%
S&P 500 (^GSPC)
71.49%

5-Year Return

RDGL
52.24%
S&P 500 (^GSPC)
70.74%

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    25.33M

  • Enterprise Value

    23.10M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    240.75

  • Price/Book (mrq)

    9.20

  • Enterprise Value/Revenue

    233.08

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -62.48%

  • Return on Equity (ttm)

    -132.51%

  • Revenue (ttm)

    99.1k

  • Net Income Avi to Common (ttm)

    -3.6M

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.34M

  • Total Debt/Equity (mrq)

    3.74%

  • Levered Free Cash Flow (ttm)

    -1.54M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: